Perspective Therapeutics (CATX) 10% Owner Lantheus Sells 35,769 Shares

What Happened Lantheus Holdings, Inc. (reported as a 10% owner via its subsidiary Lantheus Alpha Therapy, LLC) sold 35,769 shares of Perspective Therapeutics, Inc. (CATX) on September 1, 2026. The filing reports a weighted average sale price of $3.12 per share for total proceeds of $111,574. This was a sale (S) — typically routine for institutional holders and not the same signal as an insider executive purchase.

Key Details

• Transaction date: 2026-09-01; Form 4 filed: 2026-09-03 (timely filing).
• Reported price: weighted average $3.12; actual sale prices ranged from $3.08 to $3.165 across multiple trades (see footnote).
• Shares sold: 35,769; proceeds reported: $111,574.
• Post-transaction holdings: the filing shows the shares were directly held by Lantheus Alpha Therapy, LLC; the Form 4 did not disclose an aggregate post‑transaction total for Lantheus Holdings in the summary provided here.
• Footnotes: F1 explains the weighted‑average price and offers to provide per‑trade price details on request; F2 clarifies Lantheus Alpha Therapy, LLC is a wholly owned indirect subsidiary of Lantheus Holdings, so Lantheus Holdings may be deemed an indirect beneficial owner.
• Transaction type: Sale (S). No 10b5-1 plan, tax withholding, option exercise, or gift noted in this filing.

Context This is institutional selling by a 10% holder via its subsidiary, not an executive or director trade. Such dispositions are common and do not by themselves indicate management sentiment about the company’s prospects; purchases tend to be more informative about bullish insider conviction.